CA2667053C - Talarazole metabolites - Google Patents

Talarazole metabolites Download PDF

Info

Publication number
CA2667053C
CA2667053C CA2667053A CA2667053A CA2667053C CA 2667053 C CA2667053 C CA 2667053C CA 2667053 A CA2667053 A CA 2667053A CA 2667053 A CA2667053 A CA 2667053A CA 2667053 C CA2667053 C CA 2667053C
Authority
CA
Canada
Prior art keywords
compound according
talarozole
pharmaceutically acceptable
acceptable salt
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2667053A
Other languages
English (en)
French (fr)
Other versions
CA2667053A1 (en
Inventor
Debra Barrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stiefel Laboratories Inc
Original Assignee
Stiefel Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stiefel Laboratories Inc filed Critical Stiefel Laboratories Inc
Publication of CA2667053A1 publication Critical patent/CA2667053A1/en
Application granted granted Critical
Publication of CA2667053C publication Critical patent/CA2667053C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA2667053A 2006-10-17 2007-10-17 Talarazole metabolites Expired - Fee Related CA2667053C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85198906P 2006-10-17 2006-10-17
US60/851,989 2006-10-17
PCT/US2007/081685 WO2008049027A1 (en) 2006-10-17 2007-10-17 Talarazole metabolites

Publications (2)

Publication Number Publication Date
CA2667053A1 CA2667053A1 (en) 2008-04-24
CA2667053C true CA2667053C (en) 2015-04-28

Family

ID=39314359

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2667053A Expired - Fee Related CA2667053C (en) 2006-10-17 2007-10-17 Talarazole metabolites

Country Status (10)

Country Link
US (2) US8188124B2 (enExample)
EP (1) EP2114895A4 (enExample)
JP (1) JP5343267B2 (enExample)
KR (1) KR101419965B1 (enExample)
CN (1) CN101611016B (enExample)
AU (1) AU2007311026B2 (enExample)
BR (1) BRPI0718310A2 (enExample)
CA (1) CA2667053C (enExample)
MX (1) MX2009004096A (enExample)
WO (1) WO2008049027A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
US9096832B2 (en) 2007-07-31 2015-08-04 Lifescan, Inc. Differentiation of human embryonic stem cells
ATE523585T1 (de) 2007-11-27 2011-09-15 Lifescan Inc Differenzierung menschlicher embryonaler stammzellen
CA2959401C (en) 2008-02-21 2021-12-07 Centocor Ortho Biotech Inc. Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
KR101651661B1 (ko) 2008-06-30 2016-08-26 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 분화
MX2011004563A (es) 2008-10-31 2011-06-01 Centocor Ortho Biotech Inc Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico.
CN102272291B (zh) 2008-10-31 2018-01-16 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
PL2366021T3 (pl) 2008-11-20 2017-12-29 Janssen Biotech, Inc. Hodowla pluripotencjalnych komórek macierzystych na mikronośnikach
PL2366022T3 (pl) 2008-11-20 2016-11-30 Sposoby i kompozycje do przyłączania i hodowli komórek na podłożach planarnych
KR20170118969A (ko) 2009-07-20 2017-10-25 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
AU2010333839C1 (en) 2009-12-23 2016-07-21 Janssen Biotech Inc. Differentiation of human embryonic stem cells
CN107189979B (zh) 2010-03-01 2021-05-04 詹森生物科技公司 纯化衍生自多能干细胞的细胞的方法
KR101986176B1 (ko) 2010-05-12 2019-06-05 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
AU2011296381B2 (en) 2010-08-31 2016-03-31 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
WO2012030539A2 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
WO2012030540A2 (en) * 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
US9248120B2 (en) 2011-08-23 2016-02-02 The Board Of Trustees Of The Leland Stanford Junior University Reversing intestinal inflammation by inhibiting retinoic acid metabolism
US9388386B2 (en) 2011-12-22 2016-07-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
CA2866590A1 (en) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
WO2013184888A1 (en) 2012-06-08 2013-12-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
WO2014105543A1 (en) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
RU2687379C2 (ru) 2012-12-31 2019-05-13 Янссен Байотек, Инк. Суспендирование и кластеризация плюрипотентных клеток человека с целью их дифференцировки в панкреатические эндокринные клетки
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
RU2684215C2 (ru) 2012-12-31 2019-04-04 Янссен Байотек, Инк. Способ получения панкреатических эндокринных клеток (варианты) и способ увеличения выхода бета-клеток
JP6588969B2 (ja) 2014-05-16 2019-10-09 ヤンセン バイオテツク，インコーポレーテツド 膵内分泌細胞内のｍａｆａ発現を強化するための小分子の使用
JP6705911B2 (ja) 2016-04-14 2020-06-03 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞の中腸内胚葉細胞への分化

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0907650B1 (en) * 1996-06-27 2002-12-04 Janssen Pharmaceutica N.V. N- 4-(heteroarylmethyl)phenyl]-heteroarylamines
AP869A (en) 1998-01-05 2000-09-04 Pfizer 2,3-Substituted indole compounds as anti-inflammatory and analgesic agents.
IL162533A0 (en) * 2001-12-19 2005-11-20 Atherogenics Inc Chalcone derivatives and their use to treat diseases
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
PL372356A1 (pl) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods

Also Published As

Publication number Publication date
BRPI0718310A2 (pt) 2013-11-19
EP2114895A1 (en) 2009-11-11
JP2010506953A (ja) 2010-03-04
CN101611016B (zh) 2012-01-25
CA2667053A1 (en) 2008-04-24
MX2009004096A (es) 2009-06-16
JP5343267B2 (ja) 2013-11-13
US20100292284A1 (en) 2010-11-18
US20120283204A1 (en) 2012-11-08
US8188124B2 (en) 2012-05-29
AU2007311026A1 (en) 2008-04-24
WO2008049027A1 (en) 2008-04-24
KR20090068286A (ko) 2009-06-25
EP2114895A4 (en) 2011-06-22
US8399495B2 (en) 2013-03-19
AU2007311026B2 (en) 2012-05-17
KR101419965B1 (ko) 2014-07-16
CN101611016A (zh) 2009-12-23

Similar Documents

Publication Publication Date Title
AU2007311026B2 (en) Talarazole metabolites
DE60106281T2 (de) Verfahren zur Behandlung eines Östrogenrezeptor-positiven Karzinoms
DE60037664T2 (de) Langkettige n-alkyl verbindungen und deren oxa-derivate zur verwendung als anitvirale mittel
DE69717148T2 (de) 3-pyridylenantiomere und ihre verwendung als analgetika
US11827605B2 (en) Isoquinoline compounds and their use in treating AhR imbalance
FI67686C (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara fenetanolaminderivat
KR20210052507A (ko) 간 장애 치료
EP2987784A1 (de) Verbesserung der bioverfügbarkeit von wirkstoffen mit amidinfunktion in arzneimitteln
US8378112B2 (en) Glycyrrhetinic acid derivative and use thereof
US20230357240A1 (en) Novel n-heterocyclic bet bromodomain inhibitor, and preparation method thereof and medical use thereof
WO2025034606A2 (en) A clinically-translatable ros/rns molecular imaging agent using a radiolabeled derivative of edaravone (edv)
JPH085863B2 (ja) １４−アニソイルアコニンおよびそれを有効成分とする新規な鎮痛・抗炎症剤
He et al. Metabolism and disposition of moxonidine in Fischer 344 rats
Scatina et al. Metabolic disposition of enciprazine, a non-benzodiazepine anxiolytic drug, in rat, dog and man
WO2001070217A1 (en) Dna-cleaving antitumor agents
EP1412361B1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluoren-6-carbonsäurederivate als nmda-antagonisten
FR2508043A1 (fr) Derives d'aporphine efficaces par voie orale et leur procede de fabrication
WO2025097160A1 (en) Methods of enhancing levodopa therapeutic efficacy
KR820001304B1 (ko) 펜아탄올아민의 제조방법
Lan et al. Metabolism of a Benzothiazine compound (SQ 11,579) by the Intact Rat, Isolated Perfused Rat Liver, and Rat-Liver Microsomes
HK40087840A (en) Novel n-heterocyclic bet bromodomain inhibitor, and preparation method therefor and medical use thereof
Cox et al. The metabolism in animals and man of oxmetidine—A new histamine H2-receptor antagonist
JP2018516947A5 (enExample)
LU84211A1 (fr) Composes d'aporphine efficaces par voie orales
DD283372A5 (de) Verfahren zur herstellung von aminoketonen und -alkoholen

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20161017